Digital future? Sounds both expensive and confusing! Instead, let’s talk about the recent past. What stood out for FOTF in this latest fortnight-plus – extended a bit to accommodate the Thanksgiving holiday – were two vast sums of money for companies plying cutting-edge biomedical technologies that, despite some successes in previous permutations, are still high-risk.
Let’s start with the second, because it’s a more obvious case. The company is Juno Therapeutics, which has rounded up...